AstraZeneca Reports Potential Extension of Tagrisso Market Lifecycle
AstraZeneca is pursuing a combination therapy strategy to extend the clinical and commercial lifecycle of its flagship lung cancer drug, Tagrisso.

AstraZeneca has announced clinical data suggesting a combination therapy approach may extend the therapeutic utility of Tagrisso in patients with mutant non-small cell lung cancer. This development aims to prolong the duration of treatment for patients who have developed resistance to existing monotherapy protocols.
Maintaining the market position of Tagrisso is critical for the company, as the drug currently serves as a primary revenue driver within its oncology portfolio. Extending the treatment lifecycle mitigates the risk of revenue erosion from emerging competitive therapies and potential patent expirations.
Regulatory approval for this combination regimen would solidify the company's dominance in the lung cancer segment. Continued clinical success in this area remains a key indicator for the firm's long-term growth projections and R&D efficiency.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Silver diamine fluoride stops decay in over half of baby teeth
- B vitamins can turn urine fluorescent yellow
Latest news
- Hull City 2–0 Brighton: When Resilience Beat Reputation
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike

